<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790998</url>
  </required_header>
  <id_info>
    <org_study_id>3110A1-3000</org_study_id>
    <secondary_id>B1751006 - ONCBL60801</secondary_id>
    <nct_id>NCT00790998</nct_id>
  </id_info>
  <brief_title>Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection</brief_title>
  <official_title>A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines Development Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines Development Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and
      ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes
      river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1
      ratio) to receive one orally-administered dose of either moxidectin or ivermectin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin microfilaria density (mf/mg)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria density (mf/mg)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria density (mf/mg)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria density (mf/mg)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria reduction from baseline</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria reduction from baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria reduction from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin microfilaria reduction from baseline</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with undetectable levels of skin microfilaria</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with undetectable levels of skin microfilaria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with undetectable levels of skin microfilaria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with undetectable levels of skin microfilaria</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent reduction in microfilaria levels in the anterior chamber of the eye</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1497</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>Moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidectin 8mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin 150 mcg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidectin</intervention_name>
    <description>Single dose of moxidectin 2 mg oral tablet x 4</description>
    <arm_group_label>Moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4</description>
    <arm_group_label>Ivermectin</arm_group_label>
    <other_name>Ivermectin, Mectizan, Stromectol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with Onchocerca volvulus infection

        Exclusion Criteria:

          -  Pregnant or breast feeding women; coincidental loiasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Special Programme for Research and Training in Tropical Diseases (TDR)</last_name>
    <role>Study Director</role>
    <affiliation>World Health Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Recherche Clinique de Butembo - Universit√© Catholique du Graben</name>
      <address>
        <city>Butembo</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche en Maladies Tropicales de l'Ituri</name>
      <address>
        <city>Rethy</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onchocerciasis Chemotherapy Research Center</name>
      <address>
        <city>Hohoe</city>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberian Institute for Biomedical Research Clinical Research Center</name>
      <address>
        <city>Bolahun</city>
        <state>Lofa County</state>
        <country>Liberia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Ghana</country>
    <country>Liberia</country>
  </location_countries>
  <removed_countries>
    <country>Congo</country>
  </removed_countries>
  <link>
    <url>http://dx.doi.org/10.1016/S0140-6736(17)32844-1</url>
    <description>Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial</description>
  </link>
  <results_reference>
    <citation>Opoku NO, Bakajika DK, Kanza EM, Howard H, Mambandu GL, Nyathirombo A, Nigo MM, Kasonia K, Masembe SL, Mumbere M, Kataliko K, Larbelee JP, Kpawor M, Bolay KM, Bolay F, Attah SK, Vaillant M, Halleux CM, Kuesel AC. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial. Lancet. 2018 Jan 17. pii: S0140-6736(17)32844-1. doi: 10.1016/S0140-6736(17)32844-1. [Epub ahead of print]</citation>
    <PMID>29361335</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>onchocerciasis</keyword>
  <keyword>river blindness</keyword>
  <keyword>onchocerca volvulus</keyword>
  <keyword>moxidectin</keyword>
  <keyword>ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Intestinal Volvulus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Milbemycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

